[go: up one dir, main page]

NO20062426L - Benzimidazoler nyttige som modulatorer av ionekanaler - Google Patents

Benzimidazoler nyttige som modulatorer av ionekanaler

Info

Publication number
NO20062426L
NO20062426L NO20062426A NO20062426A NO20062426L NO 20062426 L NO20062426 L NO 20062426L NO 20062426 A NO20062426 A NO 20062426A NO 20062426 A NO20062426 A NO 20062426A NO 20062426 L NO20062426 L NO 20062426L
Authority
NO
Norway
Prior art keywords
modulators
ion channels
benzimidazoles useful
benzimidazoles
useful
Prior art date
Application number
NO20062426A
Other languages
English (en)
Inventor
Iii Jesus E Gonzales
Dean Mirchell Wilson
Andreas Peter Termin
Yulian Zhang
Lev Tyler Dewey Fanning
Nicole Zimmermann
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20062426L publication Critical patent/NO20062426L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)

Abstract

Forbindelser med formel I: eller et farmasøytisk akseptabelt salt derav, hvor R1-, Z-, Y-, RA-, og W-gruppene med formel I har betydningene som angis heri. Oppfinnelsen tilveiebringer også farmasøytisk akseptable sammensetninger og fremgangsmåter ved anvendelse av sammensetningene ved behandling av forskjellige forstyrrelser.
NO20062426A 2003-10-28 2006-05-29 Benzimidazoler nyttige som modulatorer av ionekanaler NO20062426L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51508803P 2003-10-28 2003-10-28
PCT/US2004/036297 WO2005042497A2 (en) 2003-10-28 2004-10-28 Benzimidazoles useful as modulators of ion channels

Publications (1)

Publication Number Publication Date
NO20062426L true NO20062426L (no) 2006-05-29

Family

ID=34549374

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062426A NO20062426L (no) 2003-10-28 2006-05-29 Benzimidazoler nyttige som modulatorer av ionekanaler

Country Status (13)

Country Link
US (2) US7309716B2 (no)
EP (1) EP1678145A2 (no)
JP (1) JP2007521325A (no)
KR (1) KR20060115396A (no)
CN (1) CN1902181A (no)
AU (1) AU2004285053B2 (no)
CA (1) CA2543918A1 (no)
IL (1) IL175252A0 (no)
NO (1) NO20062426L (no)
NZ (1) NZ547109A (no)
RU (1) RU2006118312A (no)
WO (1) WO2005042497A2 (no)
ZA (1) ZA200603864B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) * 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
FR2880889B1 (fr) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si Derives de l'acide 1h-indole-3-carboxylique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
GB0514018D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
CN101223136A (zh) * 2005-07-12 2008-07-16 拜尔农科股份有限公司 新苯并杂环基乙基苯甲酰胺衍生物
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CN101282929A (zh) * 2005-08-15 2008-10-08 Irm责任有限公司 用作tpo模拟物的化合物和组合物
EP2012774A1 (en) 2006-03-27 2009-01-14 Wex Pharmaceuticals, Inc Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
HUE030052T4 (en) 2007-06-29 2017-06-28 Pfizer Benzimidazole derivatives
JP5555169B2 (ja) * 2007-10-11 2014-07-23 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
EA028911B1 (ru) 2007-11-06 2018-01-31 Биоэлектрон Текнолоджи Корпорейшн ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
RU2379294C1 (ru) * 2008-05-19 2010-01-20 Государственное образовательное учреждение высшего профессионального образования "Российский химико-технологический университет им. Д.И. Менделеева" (РХТУ им. Д.И. Менделеева) [2-(азол-1-ил)алкилбензимидазол-1-ил]алкановые кислоты и их эфиры, способ их получения (варианты) и рострегуляторная композиция на их основе
RU2480463C1 (ru) * 2009-03-05 2013-04-27 Дайити Санкио Компани, Лимитед Пиридилокси производные, полезные в качестве активатора/модулятора гамма-рецептора, активируемого пролифератором пероксисом (ppar) гамма
WO2011158108A2 (en) 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
RU2443690C1 (ru) * 2010-12-13 2012-02-27 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации 2-(9-антрилметил)амино-1-[3-(диметиламино)пропил]бензимидазол, обладающий свойствами флуоресцентного хемосенсора на катионы h+
ES2786298T3 (es) 2011-03-03 2020-10-09 Zalicus Pharmaceuticals Ltd Inhibidores de benzimidazol del canal de sodio
WO2013042035A1 (en) * 2011-09-19 2013-03-28 Vitas Pharma Research Private Limited Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
WO2013101911A2 (en) 2011-12-28 2013-07-04 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
WO2013101926A1 (en) 2011-12-28 2013-07-04 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US20150203812A1 (en) * 2014-01-20 2015-07-23 Francesco Tombola Inhibitors of Voltage Gated Ion Channels
WO2016029146A1 (en) * 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
CN104926745A (zh) * 2015-07-14 2015-09-23 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端卤代苄基类结构的化合物及其用途
CN104974103A (zh) * 2015-07-14 2015-10-14 佛山市赛维斯医药科技有限公司 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途
EA201890532A1 (ru) * 2015-08-20 2018-09-28 Бёрингер Ингельхайм Интернациональ Гмбх Новые аннелированные бензамиды
EP3348547B1 (en) * 2015-09-11 2020-07-22 Sumitomo Dainippon Pharma Co., Ltd. Benzimidazole derivatives as nav 1.7 (sodium channel, voltage-gated, type ix, alpha subunit (scn9a)) inhibitors for treating pain, dysuria and multiple sclerosis
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
CN110770211B (zh) 2017-06-23 2023-09-19 协和麒麟株式会社 α,β不饱和酰胺化合物
KR101938982B1 (ko) 2017-07-17 2019-01-15 연세대학교 산학협력단 자가포식 조절제를 포함하는 대사성 질환 치료용 약학 조성물
KR102070882B1 (ko) * 2017-10-17 2020-01-29 성균관대학교산학협력단 Bietpc를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
JP7623275B2 (ja) 2018-07-09 2025-01-28 リーバー インスティチュート インコーポレイテッド ＮａＶ１．８を阻害するピリダジン化合物
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
CN113692276A (zh) * 2019-02-19 2021-11-23 加利福尼亚大学董事会 Nurr1受体调节剂
MA53521B1 (fr) * 2021-05-12 2023-03-31 Univ Ibn Tofail Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications
KR20240035395A (ko) 2021-06-14 2024-03-15 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료에 사용할 수 있는 요소 유도체
WO2023053059A1 (en) * 2021-09-30 2023-04-06 Universidade Do Porto Antifouling compound, method and uses thereof
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US11478464B1 (en) 2022-02-06 2022-10-25 King Faisal University Method for treating inflammation
US11786535B1 (en) 2023-02-22 2023-10-17 King Faisal University Methods of inhibiting cyclooxygenase
CN120152963B (zh) * 2023-09-28 2025-11-18 四川大学华西医院 一类镇痛的化合物及其制备方法和用途
WO2026015548A1 (en) * 2024-07-08 2026-01-15 Convelo Therapeutics, Inc. Cyp51 inhibitors and method of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL280954A (no) * 1961-07-14
US4088768A (en) * 1975-05-06 1978-05-09 Eli Lilly And Company N-heterocyclic ureas as immune regulants
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
CA2369544A1 (en) * 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives:selective modulators of bradykinin b2 receptors
JP2003502405A (ja) * 1999-06-22 2003-01-21 ニューロサーチ、アクティーゼルスカブ 新規ベンズイミダゾール誘導体及びこれらの化合物を含有する薬学的に容認された塩
US6316474B1 (en) * 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
ES2225558T3 (es) * 2000-06-13 2005-03-16 Eli Lilly And Company Derivados de sulfonamida.
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor

Also Published As

Publication number Publication date
JP2007521325A (ja) 2007-08-02
IL175252A0 (en) 2006-09-05
US20050209282A1 (en) 2005-09-22
US20080306129A1 (en) 2008-12-11
CN1902181A (zh) 2007-01-24
US7309716B2 (en) 2007-12-18
NZ547109A (en) 2010-03-26
WO2005042497A2 (en) 2005-05-12
EP1678145A2 (en) 2006-07-12
AU2004285053A1 (en) 2005-05-12
RU2006118312A (ru) 2007-12-10
KR20060115396A (ko) 2006-11-08
AU2004285053B2 (en) 2010-10-21
ZA200603864B (en) 2007-09-26
CA2543918A1 (en) 2005-05-12
WO2005042497A3 (en) 2005-07-21
US7705031B2 (en) 2010-04-27

Similar Documents

Publication Publication Date Title
NO20062426L (no) Benzimidazoler nyttige som modulatorer av ionekanaler
NO20081844L (no) Terapeutiske forbindelser
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
NO20061454L (no) Compounds having CRTH2 antagonist activity
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
NO20060518L (no) Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler
NO20050828L (no) lndol-3-svovelderivater
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
NO20082496L (no) Pyrazinderivater
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20091247L (no) terapeutiske pyrazolyl tienopyridiner
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ATE540948T1 (de) Pyrrolopyridine als proteinkinasehemmer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
NO20064000L (no) Heteroarylkoblede pyrazoloderivater
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application